Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other
pharmaceutical manufacturers in Australasia:
AFT Pharmaceuticals Ltd
of NEW ZEALAND
sales of 105.60 million New Zealand Dollars [US$74.05 million]
of which 58%
(107.22 million Australian Dollars [US$81.66 million]
Vita Life Sciences Limited.
(46.48 million Australian Dollars [US$35.40 million]
During the year ended June of 2020, sales at
Mayne Pharma Group Limited were A$457.77 million (US$348.64 million).
decrease of 13.0%
versus 2019, when the company's sales were A$526.22 million.
Contributing to the drop in overall sales was the 21.1% decline
in Generic Products, from A$320.77 million to A$253.05 million.
There were also decreases in sales in
Specialty Brands (down 14.0% to A$78.76 million)
However, these declines were partially offset by the increase in sales of
Metrics Contract Services (Mcs) (up 14.7% to A$82.82 million)
Mayne Pharma International (Mpi) (up 4.1% to A$42.36 million)